We serve 5-Acetyl-2-hydroxybenzamide CAS:40187-51-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 5-Acetyl-2-hydroxybenzamide
CAS.NO: 40187-51-7
Synonyms:
5-acetyl-2-hydroxybenzamide
5-Acetylsalicylamide
Molecular Formula:C9H9NO3
Molecular Weight: 179.17300
Physical and Chemical Properties:
Density: 1.297 g / cm3
Boiling point: 395.6ºC at 760 mmHg
Melting point: 220-222 ° C (lit.)
Flash point: 193.1ºC
Refractive index: 1.597
Specification:
Appearance: Off-white to light yellow crystalline powder
Purity:≥98.0%
Total Impurity:≤0.5%
Water:≤0.5%
Heavy metals:≤10ppm
Volatile:≤0.1%
Inorganic salt:≤0.1%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Labetalol CAS:36894-69-6.
Contact us for information like 5-Acetyl-2-hydroxybenzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Acetylsalicylamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Acetyl-2-hydroxybenzamide Use and application,5-acetyl-2-hydroxybenzamide technical grade,usp/ep/jp grade.
Related News: Both patients were being treated in isolation units at a Manila hospital.2-Bromo-4-fluoroaniline manufacturer Both patients were being treated in isolation units at a Manila hospital.1H,1H,2H,2H-Perfluorodecyltriethoxysilane supplier The StartScore model was developed by the company’s in-house supply chain experts based on actual performance data.N,N-Dimethylanilinium tetrakis(pentafluorophenyl)borate vendor The StartScore model was developed by the company’s in-house supply chain experts based on actual performance data.In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.
